Marvin M. van Luijn

1.5k citations

43 papers · 1.1k indexed · h-index 18

Co-authors: Jamie van Langelaar Joost Smolders Liza Rijvers Rogier Q. Hintzen Annet F. Wierenga‐Wolf Marie‐José Melief Malou Janssen Georges M. G. M. Verjans
Topics: Immunotherapy and Immune Responses (20 papers)T-cell and B-cell Immunology (20 papers)Multiple Sclerosis Research Studies (19 papers)
Cited by: Immunology Pathology and Forensic Medicine Neurology
Journals: The Journal of Immunology PLoS ONE Brain
Partner nations: Netherlands United States Canada

In The Last Decade

Marvin M. van Luijn

41 papers receiving 1.1k citations

Peers

Countries citing papers authored by Marvin M. van Luijn

Since Specialization

Citations

This map shows the geographic impact of Marvin M. van Luijn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marvin M. van Luijn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marvin M. van Luijn more than expected).

Fields of papers citing papers by Marvin M. van Luijn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marvin M. van Luijn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marvin M. van Luijn. The network helps show where Marvin M. van Luijn may publish in the future.

Co-authorship network of co-authors of Marvin M. van Luijn

This figure shows the co-authorship network connecting the top 25 collaborators of Marvin M. van Luijn. A scholar is included among the top collaborators of Marvin M. van Luijn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marvin M. van Luijn. Marvin M. van Luijn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Acquisition of residency programs by T cells entering the human brain 2025 ·Cell Reports ·Cheng‐Chih Hsiao,Hendrik J. Engelenburg,Jasper Rip,Annet F. Wierenga‐Wolf,(unknown),Marvin M. van Luijn,Inge Huitinga,Jörg Hamann,Joost Smolders	0
2	Antinuclear antibodies in early multiple sclerosis reflect systemic lupus erythematosus shared risk factors 2025 ·Scientific Reports ·(unknown),(unknown),(unknown),M. Kamran Ikram,Marvin M. van Luijn,Beatrijs Wokke,Joost Smolders	0
3	Perturbances in Both Circulating B and CD4 ⁺ T Cells Discriminate Multiple Sclerosis from Other Central Nervous System Autoimmune Diseases 2025 ·European Journal of Immunology ·(unknown),Jasper Rip,(unknown),(unknown),(unknown),Annet F. Wierenga‐Wolf,Marie‐José Melief,(unknown),(unknown),(unknown),Ide Smets,Beatrijs Wokke,Maarten J. Titulaer,Joost Smolders,Marvin M. van Luijn	1
4	Epstein–Barr virus and genetic risk variants as determinants of T-bet+ B cell-driven autoimmune diseases 2023 ·Immunology Letters ·(unknown),(unknown),Joost Smolders,Jasper Rip,Marvin M. van Luijn	7
5	Differential Runx3, Eomes, and T‐bet expression subdivides MS‐associated CD4 ⁺ T cells with brain‐homing capacity 2023 ·European Journal of Immunology ·(unknown),(unknown),(unknown),Jasper Rip,(unknown),Annet F. Wierenga‐Wolf,Marie‐José Melief,Piet Stinissen,Joost Smolders,Niels Hellings,Bieke Broux,Marvin M. van Luijn	7
6	Ocrelizumab associates with reduced cerebrospinal fluid B and CD20dim CD4+ T cells in primary progressive multiple sclerosis 2023 ·Brain Communications ·(unknown),(unknown),(unknown),Jasper Rip,(unknown),Annet F. Wierenga‐Wolf,Beatrijs Wokke,Marvin M. van Luijn,Joost Smolders	4
7	Selective emergence of antibody-secreting cells in the multiple sclerosis brain 2023 ·EBioMedicine ·(unknown),Hendrik J. Engelenburg,Malou Janssen,Peter‐Paul A. Unger,Marie‐José Melief,Annet F. Wierenga‐Wolf,Cheng‐Chih Hsiao,Matthew R. J. Mason,Jörg Hamann,Jamie van Langelaar,Joost Smolders,Marvin M. van Luijn	19
8	T-cell surveillance of the human brain in health and multiple sclerosis 2022 ·Seminars in Immunopathology ·Joost Smolders,Marvin M. van Luijn,Cheng‐Chih Hsiao,Jörg Hamann	17
9	Improving Glucocorticoid Sensitivity of Brain-Homing CD4+ T Helper Cells by Steroid Hormone Crosstalk 2022 ·Frontiers in Immunology ·(unknown),Jamie van Langelaar,Annet F. Wierenga‐Wolf,Marie‐José Melief,(unknown),(unknown),Erik Lubberts,Willem A. Dik,Joost Smolders,Marvin M. van Luijn	6
10	Proportions of circulating transitional B cells associate with MRI activity in interferon beta-treated multiple sclerosis patients 2021 ·Journal of Neuroimmunology ·(unknown),Jan Damoiseaux,(unknown),Linda Rolf,Anne‐Hilde Muris,Raymond Hupperts,Marvin M. van Luijn,(unknown),Joost Smolders	5
11	B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers 2020 ·Frontiers in Immunology ·Jamie van Langelaar,Liza Rijvers,Joost Smolders,Marvin M. van Luijn	192
12	The association of Epstein‐Barr virus infection with CXCR3 ⁺ B‐cell development in multiple sclerosis: impact of immunotherapies 2020 ·European Journal of Immunology ·Jamie van Langelaar,Annet F. Wierenga‐Wolf,Johnny P.A. Samijn,(unknown),Theodora A. M. Siepman,Pieter A. van Doorn,Andrew Bell,Menno C. van Zelm,Joost Smolders,Marvin M. van Luijn	26
13	Chemical and genetic control of IFN γ‐induced MHCII expression 2018 ·EMBO Reports ·Ruud H. Wijdeven,Marvin M. van Luijn,Annet F. Wierenga‐Wolf,Jimmy J.L.L. Akkermans,Peter J. van den Elsen,Rogier Q. Hintzen,Jacques Neefjes	25
14	Multiple sclerosis-associated CLEC16A controls HLA class II expression via late endosome biogenesis 2015 ·Brain ·Marvin M. van Luijn,Karim L. Kreft,Marlieke L.M. Jongsma,Steven W. Mes,Annet F. Wierenga‐Wolf,Marjan van Meurs,Marie‐José Melief,Rik van der Kant,Lennert Janssen,Hans Janssen,Rusung Tan,John J. Priatel,Jacques Neefjes,Jon D. Laman,Rogier Q. Hintzen	43
15	High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia 2014 ·Leukemia Research ·Willemijn van den Ancker,Marvin M. van Luijn,Martine E.D. Chamuleau,Angèle Kelder,N Feller,Monique Terwijn,Adri Zevenbergen,Gerrit‐Jan Schuurhuis,S. Marieke van Ham,Theresia M. Westers,Gert J. Ossenkoppele,Arjan A. van de Loosdrecht	10
16	Promiscuous Binding of Invariant Chain-Derived CLIP Peptide to Distinct HLA-I Molecules Revealed in Leukemic Cells 2012 ·PLoS ONE ·Marvin M. van Luijn,Arjan A. van de Loosdrecht,Margit H. Lampen,Peter A. van Veelen,Adri Zevenbergen,Michel G.D. Kester,Arnoud H. de Ru,Gert J. Ossenkoppele,Thorbald van Hall,S. Marieke van Ham	9
17	Tumor immune escape in acute myeloid leukemia 2012 ·OncoImmunology ·Marvin M. van Luijn,Martine E.D. Chamuleau,Gert J. Ossenkoppele,Arjan A. van de Loosdrecht,S. Marieke van Ham	10
18	Absence of Class II–Associated Invariant Chain Peptide on Leukemic Blasts of Patients Promotes Activation of Autologous Leukemia-Reactive CD4+ T Cells 2011 ·Cancer Research ·Marvin M. van Luijn,Willemijn van den Ancker,Martine E.D. Chamuleau,Adri Zevenbergen,Theresia M. Westers,Gert J. Ossenkoppele,S. Marieke van Ham,Arjan A. van de Loosdrecht	23
19	Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation 2010 ·Cancer Immunology Immunotherapy ·Willemijn van den Ancker,Marvin M. van Luijn,Jurjen M. Ruben,Theresia M. Westers,Hetty J. Bontkes,Gert J. Ossenkoppele,Tanja D. de Gruijl,Arjan A. van de Loosdrecht	12
20	Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses 2009 ·Haematologica ·Marvin M. van Luijn,Martine E.D. Chamuleau,James A. Thompson,Suzanne Ostrand‐Rosenberg,Theresia M. Westers,Yuri Souwer,G.J. Ossenkoppele,S. Marieke van Ham,Arjan A. van de Loosdrecht	21

About Marvin M. van Luijn

Marvin M. van Luijn is a scholar working on Immunology, Pathology and Forensic Medicine and Neurology, having authored 43 papers that have together received 1.1k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (20 papers), T-cell and B-cell Immunology (20 papers) and Multiple Sclerosis Research Studies (19 papers). The work is most often cited by research in Immunology (571 citations), Pathology and Forensic Medicine (434 citations) and Neurology (190 citations). Marvin M. van Luijn has collaborated with scholars based in Netherlands, United States and Canada. Frequent co-authors include Jamie van Langelaar, Joost Smolders, Liza Rijvers, Rogier Q. Hintzen, Annet F. Wierenga‐Wolf, Marie‐José Melief, Malou Janssen, Georges M. G. M. Verjans, Theodora A. M. Siepman and Helga E. de Vries. Their work appears in journals such as The Journal of Immunology, PLoS ONE and Brain.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact